Cancer

VICC trial putting lung cancer therapy to the test

Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis.

Cancer disparities grant with Meharry, TSU gains renewal

A multi-year collaborative cancer research effort among Vanderbilt University Medical Center (VUMC), Meharry Medical College (MMC) and Tennessee State University (TSU) will receive continued federal funding through the renewal of U54 Partners in Eliminating Cancer Disparities Grants from the National Cancer Institute (NCI), a division of the National Institutes of Health.

BMI genotype and breast cancer risk

For breast cancer prevention, a new study provides evidence for lifestyle modification to reduce weight gain in adults.

New prostate cancer therapy investigated at VUMC

Vanderbilt University Medical Center is the world’s first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation.

VUMC’s Lehman lands LUNGevity research support

Jonathan Lehman, M.D., Ph.D., instructor in Medicine in the Division of Hematology/Oncology, has received a Career Development Award from LUNGevity, a nonprofit organization that provides support programs for lung cancer patients and families, public education and funding for innovative scientific research.

National Lymphedema Network honors VUMC research efforts

Lymphedema research conducted at Vanderbilt University Medical Center (VUMC) to better understand patient risk for this chronic condition and treatment responses received recognition at an international conference.

1 39 40 41 42 43 67